| Budach, Wilfried |
| Recruiting | 3 | 1826 | Europe | preoperative radiotherapy, postoperative radiotherapy | Prof. Dr. Christiane Matuschek | Breast Cancer | 03/28 | 03/34 | | |
| Completed | 2 | 120 | Europe | Durvalumab + Tremelimumab + RT | University of Erlangen-Nürnberg Medical School | Locally Advanced Head and Neck Squamous Cell Carcinoma | 09/21 | 02/24 | | |
| Completed | 2 | 115 | Europe | A (pembrolizumab+RT), Keytruda + RT, B (pembrolizumab), Keytruda | University of Erlangen-Nürnberg Medical School, Medical Faculty of the Friedrich-Alexander University Erlangen-Nürnberg | Head and Neck Squamous Cell Carcinoma | 10/24 | 10/24 | | |
C-O-MET, NCT02887651: Cavity Boost Radiation Therapy vs. Observation in Cerebral Metastases After Complete Surgical Resection |
|
|
| Recruiting | N/A | 108 | Europe | Cavity boost radiation | Heinrich-Heine University, Duesseldorf | Cerebral Metastases, Surgery | 12/23 | 12/24 | | |
| Fehm, Tanja |
CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients |
|
|
| Recruiting | 4 | 1000 | Europe | Ribociclib | Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals | Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer | 10/24 | 10/26 | | |
| Active, not recruiting | 3 | 654 | Europe, Canada, Japan, US, RoW | Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo | Seagen Inc., Merck Sharp & Dohme LLC | HER2 Positive Breast Cancer | 05/25 | 10/27 | | |
ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease |
|
|
| Active, not recruiting | 3 | 43 | Europe, Canada, Japan, US, RoW | Niraparib, Placebo | GlaxoSmithKline | Neoplasms, Breast | 06/24 | 12/25 | | |
|
| Recruiting | 3 | 1260 | Europe | Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios | West German Study Group, Eli Lilly and Company, Genomic Health®, Inc. | Breast Cancer Female | 08/26 | 03/28 | | |
| Active, not recruiting | 3 | 1332 | Europe | Capecitabine, Xeloda, Carboplatin, Paraplatin, Cisplatin, Platinol, Sacituzumab govitecan, Trodelvy | German Breast Group, Gilead Sciences, Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group (GEICAM), ETOP IBCSG Partners Foundation, Cancer Trials Ireland, UNICANCER | HER2-negative Breast Cancer, Triple Negative Breast Cancer | 03/27 | 03/29 | | |
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC |
|
|
| Active, not recruiting | 3 | 1684 | Europe | Ribociclib 200Mg Oral Tablet, Kisqali | West German Study Group, Novartis, Genomic Health®, Inc. | Breast Cancer Female | 07/27 | 07/27 | | |
| Recruiting | 3 | 1826 | Europe | preoperative radiotherapy, postoperative radiotherapy | Prof. Dr. Christiane Matuschek | Breast Cancer | 03/28 | 03/34 | | |
| Active, not recruiting | 2 | 136 | Europe | Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine | AGO Research GmbH, ImmunoGen, Inc. | Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma | 12/25 | 12/26 | | |
COMPRENDO, NCT05033756: Comprehensive Analysis of Predictors of the Treatment With Pembrolizumab and Olaparib in Patients With Unresectable or Metastatic HER2 Negative Breast Cancer and a Deleterious Germline Mutation or a Homologous Recombination Deficiency ( |
|
|
| Active, not recruiting | 2 | 11 | Europe | Pembrolizumab Injection [Keytruda], Keytruda, Olaparib Oral Tablet [Lynparza], Lynparza | Institut fuer Frauengesundheit, Merck Sharp & Dohme LLC | Malignant Neoplasm of Breast, Breast Cancer | 01/25 | 02/26 | | |
DETECT-IVa, NCT02035813: DETECT IV - A Study in Patients With HER2-negative Metastatic Breast Cancer and Persisting HER2-negative Circulating Tumor Cells (CTCs). |
|
|
| Completed | 2 | 116 | Europe | Ribociclib, Kisqali, Eribulin, Halaven | Prof. Wolfgang Janni | HER2-negative and Hormone-receptor Positive Metastatic Breast Cancer, HER2-negative Circulating Tumor Cells, Postmenopausal Female Patients | 01/24 | 01/24 | | |
ELENA, NCT05560646: A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants Aged 18 to 49 With Moderate to Severe Endometriosis-related Pain |
|
|
| Active, not recruiting | 2 | 380 | Europe, US, RoW | OG-6219, Placebo | Organon and Co, Iqvia Pty Ltd | Endometriosis | 05/25 | 05/25 | | |
| Active, not recruiting | 2 | 180 | Europe | OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475 | ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC | Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer | 12/25 | 12/25 | | |
| Recruiting | 1/2 | 68 | Europe, US, RoW | Elacestrant, Elacestrant dihydrochloride, RAD-1901, ER-306323, Orserdu, Abemaciclib, Verzenio | Stemline Therapeutics, Inc., Stemline Therapeutics, Inc | Breast Neoplasms, Brain Neoplasms, Neoplasms by Site, Neoplasms, Breast Diseases, Central Nervous System Neoplasms, Brain Diseases, Central Nervous System Diseases | 12/25 | 12/25 | | |
| Active, not recruiting | N/A | 989 | Europe, Canada, Japan, RoW | SLN biopsy only, SLN biopsy + PLN dissection | Centre Hospitalier Universitaire de Besancon, ARCAGY/ GINECO GROUP, European Network of Gynaecological Oncological Trial Groups (ENGOT) | Cervical Cancer | 05/27 | 05/29 | | |
| Prof, Christiane M |
| Recruiting | 3 | 1826 | Europe | preoperative radiotherapy, postoperative radiotherapy | Prof. Dr. Christiane Matuschek | Breast Cancer | 03/28 | 03/34 | | |
